netFormulary NHS
Milton Keynes Formulary
Milton Keynes University Hospital NHS Foundation Trust
Milton Keynes Clinical Commissioning Group
Milton Keynes Community Health Services
 Formulary Chapter 6: Endocrine system - Full Chapter
Chapter Links...
 Details...  Expand sub section  Other antidiabetic drugs  Expand sub section  Alpha glucosidase inhibitors
Acarbose (Glucobay)
View adult BNF View SPC online View childrens BNF

Tablets 50mg, 100mg


Note: Acarbose should be taken or chewed with the first mouthful of food or swallowed whole with liquid immediately before food. The possibility of GI side effects is reduced by lower incremental dosage increases  Expand sub section  DPP4 inhibitors (gliptins)  Expand sub section  GLP1 agonists  Expand sub section  Meglitinides to top  Expand sub section  SGL2 inhibitors  Expand sub section  Thiazolidinediones
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Track Changes
Display tracking information
click to search
Link to adult BNF
click to search
Link to children's BNF
click to search
Link to SPCs
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHS England

Traffic Light Status Information

Status Description


Routine prescribing within licensed indication  

Amber 1

Specialist recommendation followed by GP initiation and continuation  

Amber 2

Specialist or GP initiation in line with local guideline after 1st line failure followed by GP continuation   

Amber 3

Specialist initiation and stabilisation followed by GP continuation  

Amber SCG

Specialist initiation and stabilisation followed by GP continuation in line with an agreed shared care guideline  


Hospital or specialist prescribing only  

Red Red

These medicines have been evaluated and rejected by MKPAG and are NOT approved for use within MK. They are not recommended for use because of lack of clinical effectiveness, cost effectiveness or safety.